{"id":23310,"date":"2026-03-08T19:26:01","date_gmt":"2026-03-08T13:56:01","guid":{"rendered":"https:\/\/johnsonfrancis.org\/general\/?p=23310"},"modified":"2026-03-11T04:17:51","modified_gmt":"2026-03-10T22:47:51","slug":"hypertrophic-cardiomyopathy-management-overview","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/general\/hypertrophic-cardiomyopathy-management-overview\/","title":{"rendered":"Hypertrophic Cardiomyopathy Management Overview"},"content":{"rendered":"<iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/uV8Wyk5BD14?si=U-X6uavYFRfePfkB\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n\n<p class=\"wp-block-paragraph\">The management of Hypertrophic Cardiomyopathy (HCM) has evolved significantly, shifting from purely symptomatic relief to a comprehensive strategy focused on sudden cardiac death (SCD) prevention and specialized interventions for outflow tract obstruction.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Comprehensive Management Strategy<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Medical Management (First-Line)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The primary goal is to improve diastolic filling and reduce the pressure gradient across the Left Ventricular Outflow Tract (LVOT).<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Beta-Blockers:<\/strong> The cornerstone of therapy (e.g., Metoprolol, Atenolol). They decrease heart rate, increase diastolic filling time, and reduce ionotropic response.<\/li>\n\n\n\n<li class=\"\"><strong>Calcium Channel Blockers:<\/strong> Non-dihydropyridines like <strong>Verapamil<\/strong> are used if beta-blockers are poorly tolerated or ineffective.\n<ul class=\"wp-block-list\">\n<li class=\"\"><em>Caution:<\/em> Avoid in patients with severe resting obstruction or heart failure.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li class=\"\"><strong>Disopyramide:<\/strong> An anti-arrhythmic with negative inotropic effects, often added to beta-blockers to further reduce LVOT gradients.<\/li>\n\n\n\n<li class=\"\"><strong>Mavacamten:<\/strong> A newer, first-in-class cardiac myosin inhibitor specifically approved for symptomatic obstructive HCM.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Sudden Cardiac Death (SCD) Risk Stratification<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">All patients must be assessed for an <strong>Implantable Cardioverter-Defibrillator (ICD)<\/strong> based on:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\">Prior cardiac arrest or sustained Ventricular Tachycardia (VT).<\/li>\n\n\n\n<li class=\"\">Family history of premature HCM-related death.<\/li>\n\n\n\n<li class=\"\">Massive left ventricular hypertrophy (wall thickness \u2265 30mm).<\/li>\n\n\n\n<li class=\"\">Unexplained syncope.<\/li>\n\n\n\n<li class=\"\">Apical aneurysms or low LVEF (&lt; 50%).<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Genetic Analysis in HCM<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Genetic testing is a Class I recommendation for patients with a clinical diagnosis of HCM. It serves two primary purposes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Etiology Clarification:<\/strong> Identifying &#8220;HCM mimics&#8221; such as <strong>Fabry disease<\/strong>, <strong>Friedreich\u2019s ataxia<\/strong>, or <strong>ATTR amyloidosis<\/strong>, which require entirely different treatment pathways.<\/li>\n\n\n\n<li class=\"\"><strong>Cascade Screening:<\/strong> Once a pathogenic variant is found in the &#8220;proband&#8221; (the affected patient), first-degree relatives can be tested.\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Genotype-negative relatives<\/strong> can generally be discharged from regular clinical surveillance.<\/li>\n\n\n\n<li class=\"\"><strong>Genotype-positive relatives<\/strong> require longitudinal monitoring (ECG\/Echo) even if currently asymptomatic.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li class=\"\"><strong>Common Genes:<\/strong> Most mutations occur in the cardiac sarcomere, specifically <a href=\"https:\/\/www.acc.org\/latest-in-cardiology\/ten-points-to-remember\/2024\/07\/15\/16\/32\/genetics-of-hypertrophic-cardiomyopathy\" type=\"link\" id=\"https:\/\/www.acc.org\/latest-in-cardiology\/ten-points-to-remember\/2024\/07\/15\/16\/32\/genetics-of-hypertrophic-cardiomyopathy\"><strong>MYH7<\/strong> (Beta-myosin heavy chain) and <strong>MYBPC3<\/strong> (Myosin-binding protein C)<\/a>.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Alcohol Septal Ablation<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">ASA is a percutaneous (non-surgical) intervention for patients with <strong>obstructive HCM<\/strong> who remain symptomatic despite optimal medical therapy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">The Procedure<\/h3>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li class=\"\"><strong>Localization:<\/strong> A tiny amount of absolute ethanol (95-98%) is injected into a specific <strong>septal perforator artery<\/strong>.<\/li>\n\n\n\n<li class=\"\"><strong>Controlled Infarction:<\/strong> The alcohol causes a localized &#8220;planned myocardial infarction&#8221; of the basal septum.<\/li>\n\n\n\n<li class=\"\"><strong>Remodeling:<\/strong> The infarcted tissue thins and scars over time, widening the LVOT and reducing the pressure gradient and mitral valve systolic anterior motion (SAM).<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">ASA vs. Surgical Myectomy<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Feature<\/strong><\/td><td><strong>Alcohol Septal Ablation (ASA)<\/strong><\/td><td><strong>Septal Myectomy (Surgery)<\/strong><\/td><\/tr><\/thead><tbody><tr><td><strong>Invasiveness<\/strong><\/td><td>Minimally invasive (catheter-based)<\/td><td>Open-heart surgery<\/td><\/tr><tr><td><strong>Recovery<\/strong><\/td><td>Shorter hospital stay<\/td><td>Longer recovery period<\/td><\/tr><tr><td><strong>Common Risk<\/strong><\/td><td><strong>Permanent Pacemaker<\/strong> requirement (due to Heart Block)<\/td><td>Less risk of complete heart block<\/td><\/tr><tr><td><strong>Effectiveness<\/strong><\/td><td>Highly effective; results depend on vascular anatomy<\/td><td>The &#8220;Gold Standard&#8221; for long-term relief<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">ASA is generally preferred for older patients or those with significant comorbidities, whereas Myectomy is often favored for younger patients or those with concomitant mitral valve disease.<\/p>\n<\/blockquote>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n","protected":false},"excerpt":{"rendered":"<p>The management of Hypertrophic Cardiomyopathy (HCM) has evolved significantly, shifting from purely symptomatic relief to a comprehensive strategy focused on sudden cardiac death (SCD) prevention and specialized interventions for outflow tract obstruction. Comprehensive Management Strategy Medical Management (First-Line) The primary goal is to improve diastolic filling and reduce the pressure gradient across the Left Ventricular [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":23312,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[7],"tags":[],"class_list":["post-23310","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hypertrophic Cardiomyopathy Management Overview - All About Heart And Blood Vessels<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/general\/hypertrophic-cardiomyopathy-management-overview\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hypertrophic Cardiomyopathy Management Overview - All About Heart And Blood Vessels\" \/>\n<meta property=\"og:description\" content=\"The management of Hypertrophic Cardiomyopathy (HCM) has evolved significantly, shifting from purely symptomatic relief to a comprehensive strategy focused on sudden cardiac death (SCD) prevention and specialized interventions for outflow tract obstruction. Comprehensive Management Strategy Medical Management (First-Line) The primary goal is to improve diastolic filling and reduce the pressure gradient across the Left Ventricular [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/general\/hypertrophic-cardiomyopathy-management-overview\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Heart And Blood Vessels\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-08T13:56:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-10T22:47:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/general\/wp-content\/uploads\/2026\/03\/Hypertrophic-Cardiomyopathy-Management-Overview-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/hypertrophic-cardiomyopathy-management-overview\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/hypertrophic-cardiomyopathy-management-overview\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/#\\\/schema\\\/person\\\/f35ea33ecf9c9923597de2691ebed1a7\"},\"headline\":\"Hypertrophic Cardiomyopathy Management Overview\",\"datePublished\":\"2026-03-08T13:56:01+00:00\",\"dateModified\":\"2026-03-10T22:47:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/hypertrophic-cardiomyopathy-management-overview\\\/\"},\"wordCount\":447,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/hypertrophic-cardiomyopathy-management-overview\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Hypertrophic-Cardiomyopathy-Management-Overview-1.jpg\",\"articleSection\":[\"General\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/hypertrophic-cardiomyopathy-management-overview\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/hypertrophic-cardiomyopathy-management-overview\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/hypertrophic-cardiomyopathy-management-overview\\\/\",\"name\":\"Hypertrophic Cardiomyopathy Management Overview - All About Heart And Blood Vessels\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/hypertrophic-cardiomyopathy-management-overview\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/hypertrophic-cardiomyopathy-management-overview\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Hypertrophic-Cardiomyopathy-Management-Overview-1.jpg\",\"datePublished\":\"2026-03-08T13:56:01+00:00\",\"dateModified\":\"2026-03-10T22:47:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/#\\\/schema\\\/person\\\/f35ea33ecf9c9923597de2691ebed1a7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/hypertrophic-cardiomyopathy-management-overview\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/hypertrophic-cardiomyopathy-management-overview\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/hypertrophic-cardiomyopathy-management-overview\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Hypertrophic-Cardiomyopathy-Management-Overview-1.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Hypertrophic-Cardiomyopathy-Management-Overview-1.jpg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/hypertrophic-cardiomyopathy-management-overview\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hypertrophic Cardiomyopathy Management Overview\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/\",\"name\":\"All About Heart And Blood Vessels\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/#\\\/schema\\\/person\\\/f35ea33ecf9c9923597de2691ebed1a7\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/general\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hypertrophic Cardiomyopathy Management Overview - All About Heart And Blood Vessels","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/general\/hypertrophic-cardiomyopathy-management-overview\/","og_locale":"en_US","og_type":"article","og_title":"Hypertrophic Cardiomyopathy Management Overview - All About Heart And Blood Vessels","og_description":"The management of Hypertrophic Cardiomyopathy (HCM) has evolved significantly, shifting from purely symptomatic relief to a comprehensive strategy focused on sudden cardiac death (SCD) prevention and specialized interventions for outflow tract obstruction. Comprehensive Management Strategy Medical Management (First-Line) The primary goal is to improve diastolic filling and reduce the pressure gradient across the Left Ventricular [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/general\/hypertrophic-cardiomyopathy-management-overview\/","og_site_name":"All About Heart And Blood Vessels","article_published_time":"2026-03-08T13:56:01+00:00","article_modified_time":"2026-03-10T22:47:51+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/johnsonfrancis.org\/general\/wp-content\/uploads\/2026\/03\/Hypertrophic-Cardiomyopathy-Management-Overview-1.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/general\/hypertrophic-cardiomyopathy-management-overview\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/general\/hypertrophic-cardiomyopathy-management-overview\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/general\/#\/schema\/person\/f35ea33ecf9c9923597de2691ebed1a7"},"headline":"Hypertrophic Cardiomyopathy Management Overview","datePublished":"2026-03-08T13:56:01+00:00","dateModified":"2026-03-10T22:47:51+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/general\/hypertrophic-cardiomyopathy-management-overview\/"},"wordCount":447,"commentCount":0,"image":{"@id":"https:\/\/johnsonfrancis.org\/general\/hypertrophic-cardiomyopathy-management-overview\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/general\/wp-content\/uploads\/2026\/03\/Hypertrophic-Cardiomyopathy-Management-Overview-1.jpg","articleSection":["General"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/johnsonfrancis.org\/general\/hypertrophic-cardiomyopathy-management-overview\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/general\/hypertrophic-cardiomyopathy-management-overview\/","url":"https:\/\/johnsonfrancis.org\/general\/hypertrophic-cardiomyopathy-management-overview\/","name":"Hypertrophic Cardiomyopathy Management Overview - All About Heart And Blood Vessels","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/general\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/general\/hypertrophic-cardiomyopathy-management-overview\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/general\/hypertrophic-cardiomyopathy-management-overview\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/general\/wp-content\/uploads\/2026\/03\/Hypertrophic-Cardiomyopathy-Management-Overview-1.jpg","datePublished":"2026-03-08T13:56:01+00:00","dateModified":"2026-03-10T22:47:51+00:00","author":{"@id":"https:\/\/johnsonfrancis.org\/general\/#\/schema\/person\/f35ea33ecf9c9923597de2691ebed1a7"},"breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/general\/hypertrophic-cardiomyopathy-management-overview\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/general\/hypertrophic-cardiomyopathy-management-overview\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/general\/hypertrophic-cardiomyopathy-management-overview\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/general\/wp-content\/uploads\/2026\/03\/Hypertrophic-Cardiomyopathy-Management-Overview-1.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/general\/wp-content\/uploads\/2026\/03\/Hypertrophic-Cardiomyopathy-Management-Overview-1.jpg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/general\/hypertrophic-cardiomyopathy-management-overview\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/general\/"},{"@type":"ListItem","position":2,"name":"Hypertrophic Cardiomyopathy Management Overview"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/general\/#website","url":"https:\/\/johnsonfrancis.org\/general\/","name":"All About Heart And Blood Vessels","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/general\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/johnsonfrancis.org\/general\/#\/schema\/person\/f35ea33ecf9c9923597de2691ebed1a7","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/general\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/posts\/23310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/comments?post=23310"}],"version-history":[{"count":5,"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/posts\/23310\/revisions"}],"predecessor-version":[{"id":23317,"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/posts\/23310\/revisions\/23317"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/media\/23312"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/media?parent=23310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/categories?post=23310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/general\/wp-json\/wp\/v2\/tags?post=23310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}